Multiple Sclerosis (MS): Body Impacts, Treatments, and Living Well

MS is a chronic immune-mediated demyelinating disease of the central nervous system (brain, spinal cord, optic nerves). Onset typically 20–40 years; 3:1 female:male.

Common Symptoms

  • Fatigue (80%), weakness, spasticity
  • Numbness, paresthesia, Lhermitte's sign
  • Vision loss (optic neuritis), diplopia, nystagmus
  • Ataxia, gait impairment, tremor
  • Bladder/bowel dysfunction, sexual dysfunction
  • Cognitive changes (processing speed, memory)
  • Depression, anxiety

Disease Courses

  • Relapsing-Remitting (RRMS) — 85% at onset
  • Secondary Progressive (SPMS)
  • Primary Progressive (PPMS) — 15%

Disease-Modifying Therapies (DMTs)

  • Injectables: Interferon-β, glatiramer acetate
  • Oral: Dimethyl fumarate, fingolimod, siponimod, teriflunomide, cladribine
  • Infusion: Natalizumab, ocrelizumab, alemtuzumab, ofatumumab
  • Mechanisms: Immune modulation, sequestration, depletion, BBB protection

Symptomatic & Rehabilitative Care

  • Dalfampridine (walking), baclofen/tizanidine (spasticity), anticholinergics (bladder)
  • PT/OT, cognitive rehab, psychological support

Resources

  • National MS Society (NMSS)
  • MS International Federation
  • Specialized MS centers (multidisciplinary)

Early DMT initiation improves long-term outcomes. Treat to target: no evidence of disease activity (NEDA).

Multiple Sclerosis - Related Articles